Figure 3.

Scatter plots showing TTP on prior systemic therapies and study therapy. The study therapies are celecoxib (COX) (A) and EGFR inhibitors cetuximab and panitumumab (B). TTP was defined as duration from time of initiation of therapy to its discontinuation for any reason.
Abbreviations: EGFR, epidermal growth factor receptor; TTP, time to progression.